The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.

Plozasiran is an apoC-III-directed small interfering ribonucleic acid designed to reduce levels of hepatic and serum apoC-III ...

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire ...

"Developing new ways to treat these patients is of the utmost importance," Dr. Casey H. Halpern, a senior author of the study ...

In recent weeks, at least 23 infants in the U.S. have been infected with botulism in an outbreak linked to ByHeart powdered ...

For more than 20 years, hormone therapy for menopause has carried a warning label from the Food and Drug Administration ...

(WJW) – The recall of a baby formula believed to be linked to multiple botulism cases is now being expanded to include all ...

The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals' drug for a type of genetic disorder that causes ...

Risk of “acute, serious, and life-threatening” heart inflammation is now on the label of Sarepta's gene therapy for Duchenne ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

The West Health-Gallup survey finds almost half of adults say they’re worried they won’t be able to afford health care in 2026.